

# Cosmetics Europe Assessment of Non-Animal Approaches for Predicting Skin Sensitization

Poster  
ID 769

Martina Klaric<sup>1</sup>, Nathalie Alépée<sup>2</sup>, Dave Allen<sup>3</sup>, Takao Ashikaga<sup>4</sup>, Warren Casey<sup>5</sup>, Elodie Clouet<sup>6</sup>, Magalie Cluzel<sup>7</sup>, Aurelia Del Bufalo<sup>2</sup>, Nikki Gellatly<sup>8</sup>, Carsten Goebel<sup>9</sup>, Sebastian Hoffmann<sup>10</sup>, Petra Kern<sup>11</sup>, Jochen Kühn<sup>12</sup>, Karsten R. Mewes<sup>13</sup>, Masaaki Miyazawa<sup>14</sup>, Dirk Petersohn<sup>13</sup>, Judy Strickland<sup>3</sup>, Erwin Van Vliet<sup>15</sup>, Dan Zang<sup>3</sup>, Nicole Kleinstreuer<sup>5</sup>  
1-Cosmetics Europe, Brussels, Belgium, 2-L'Oréal, Paris, France, 3-Integrated Laboratory Systems, Inc, Research Triangle Park, NC, United States, 4-Shiseido, Kanagawa, Japan, 5-NICEATM, Research Triangle Park, NC, United States, 6-Pierre Fabre, Castres, France, 7-LVMH, St Jean de Braye, France, 8-Unilever, Bedford, United Kingdom, 9-Coty, Darmstadt, Germany, 10-SEH Consulting Services, Paderborn, Germany, 11-Procter & Gamble, Strombeek-Bever, Belgium, 12-Beiersdorf AG, Hamburg, Germany, 13-Henkel AG, Duesseldorf, Germany, 14-KAO, Tochigi, Japan, 15-SeCAM, Magliaso, Switzerland

## Abstract

Skin sensitization is a toxicity endpoint of widespread concern, for which non-animal testing approaches are available. Cosmetics Europe and the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods analysed the performance of multiple non-animal data integration approaches for the skin sensitization safety assessment. We collected and generated data on 128 substances in multiple in vitro and in chemico skin sensitization assays which are key components of various non-animal defined approaches to testing and assessment that have been submitted to the OECD as case studies for skin sensitization. LLNA and human sensitization data were used to evaluate the performance of multiple non-animal testing strategies for hazard and potency characterization. Defined approaches examined include consensus methods, artificial neural networks, support vector machine models and decision tree, all of which were reproduced using open source software tools.

## Introduction

Cosmetics Europe's Skin Tolerance Task Force's aim is to provide regulatory accepted non-animal test strategies that enable cosmetic industries to conduct skin sensitization safety assessments. To reach this aim, a program of four phases has been devised. In Phase I, 16 individual test methods were evaluated in detail, prioritising six test methods. Data for 128 substances tested in these methods were compiled in a database in addition to curated results of LLNA and human potency categories. We evaluated the predictivity of six defined approaches (DA):-BASF '2 out of 3', ICCVAM SVM, KAO STS and ITS, P&G BN ITS, Shiseido ANN. Multiple non-animal testing strategies incorporating *in vitro*, *in chemico*, and *in silico* inputs demonstrated comparable or superior accuracy to the LLNA when the prediction was compared to either animal or human data for skin sensitization. We propose our database and the open source software tools as a point of reference for the evaluation and development of DA and encourage the community to use it to meet the challenge of conducting skin sensitisation safety assessment without generating new animal data.

## Project overview and results

### Phase I

#### Method Identification & Prioritisation


Systematic evaluation of 16 test methods using predefined criteria and data on 10 substances Detailed understanding allowed prioritisation of six test methods covering key events of AOP

Prioritised: DPRA, U-SENS, KeratinoSens™, SENS-IS, h-CLAT, PPRA (ongoing)



### Phase IV

#### Risk assessment case studies for cosmetic ingredients



### OBJECTIVE

Skin sensitization risk assessment of cosmetic ingredients  
• without animal testing  
• accepted by regulators


### Phase III

#### Assessment of applicability domains

Blinded testing (blind) of 43 challenging substances of high importance for cosmetic industry

#### Optimisation of DA

- amend existing DAs providing potency information  
- explore the use of SENS-IS and PPRA in DAs




Distribution of chemicals selected for phase III

### Phase II- description

#### Data Collection, Generation and Compilation

- Substance selection**  
- 98 substances from Basketter et al., 2014  
- human data available and categorised  
- LLNA data available  
- 30 fragrances in collaboration with RIFM (human and LLNA data available)
- Data collection**  
- all existing primary output data of 6 test methods for the 128 substances  
- all existing LLNA data fulfilling quality criteria (curated by ILS)
- Data generation**  
- blinded testing to fill data gaps for the 6 test methods  
- quality checked  
- assignment of human categories for RIFM set
- Data compilation**  
- storage of all data in ambit database  
- public access planned



#### Assessment of Testing Strategies

- Qualitative characterisation of 12 skin sensitisation DA/IATA case studies against defined criteria
- Evaluation of the predictive performance of six DA/IATA case studies using database  
- reproduced algorithms  
- independent assessment with the same sets of reference data

Approach	Description
BASF '2 out of 3' approach	Implementation of an IATA into a pipeline tool (IATA-SS)
ICCVAM Support Vector Machine (SVM) approach	Data from KeratinoSens and Kinetic Peptide Assesment
Kao ITS Score-based battery system	Global Versus Domain-Based Assessment
Kao STS Sequential Testing Strategy	L'Oréal's decision strategy using a "staking" meta-model
P&G Bayesian Network Integrated Testing Strategy (ITS)	RIVM RIVM Sequential Testing Strategy
Shiseido Artificial Neural Network for predicting LLNA EC3	Unilever IATA for Skin Sensitisation Risk Assessment
	JRC Consensus of classification trees



## Phase II- results

### Comparison of human and LLNA reference data

6 DA were assessed for prediction of sensitisation hazard & potency prediction:  
- defined approaches vary in complexity and required resources  
- provide comparable or superior performance to the LLNA compared to human data  
- Propose our database and open source software tools as a point of reference for the scientific community

### DA assessment: hazard ID

Defined Approach:	Predicting Human Hazard							
	BASF 2/3 (DKH)	Kao STS	Kao ITS	ICCVAM SVM (Human)	Shiseido ANN (D_hC)	Shiseido ANN (D_hC_KS)	P&G BN ITS-3	LLNA
N	127	126	120	120	126	126	119	128
Accuracy (%)*	77.2	80.2	85.0	81.7	78.6	78.6	75.6	74.2
Sensitivity (%)	79.3	97.7	93.8	86.4	95.4	100	81.3	85.2
Specificity (%)	72.5	41.0	66.7	71.8	41.0	30.8	64.1	50.0

Defined Approach:	Predicting LLNA Hazard						
	BASF 2/3 (DKH)	Kao STS	Kao ITS	ICCVAM SVM (LLNA)	Shiseido ANN (D_hC)	Shiseido ANN (D_hC_KS)	P&G BN ITS-3
N	127	126	120	120	126	126	119
Accuracy (%)*	70.1	77.8	79.2	84.2	76.2	81.0	83.2
Sensitivity (%)	72.3	92.6	85.6	86.7	90.4	97.9	83.2
Specificity (%)	63.6	34.4	60.0	76.7	34.4	31.3	83.3

### DA assessment: potency prediction\*

Defined Approach:	Predicting Human Potency (Strong, Weak, Non sensitizers)					
	Kao STS	Kao ITS	Shiseido ANN (D_hC)	Shiseido ANN (D_hC_KS)	P&G BN ITS-3	LLNA
N	126	120	126	126	115	128
Accuracy (%)*	63.5	69.2	61.1	62.7	54.8	59.4
Overpredicted (%)	22.2	13.3	22.2	25.4	20.0	19.5
Underpredicted (%)	14.3	17.5	16.7	11.9	25.2	21.1

Defined Approach:	Predicting LLNA Potency (Strong, Weak, Non sensitizers)				
	Kao STS	Kao ITS	Shiseido ANN (D_hC)	Shiseido ANN (D_hC_KS)	P&G BN ITS-3
N	126	120	126	126	115
Accuracy (%)*	67.5	66.7	65.1	69.8	67.8
Overpredicted (%)	21.4	14.2	21.4	23.0	12.2
Underpredicted (%)	11.1	19.2	13.5	7.1	20.0

\*3-classes: strong, weak and NS

This work was sponsored by Cosmetics Europe